June 19, 2013 2:13 PM ET

Pharmaceuticals

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. develops oral therapeutics to correct mineral metabolism and metabolic disorders. It offers RDX5791, a potent and selective inhibitor of NHE3, a sodium transporter on the surface of the intestinal epithelia; and RDX002, a minimally-systemic phosphate transport inhibitors targeting the intestinal phosphate transporter NaP2b for the treatment of phosphorus disorders associated with chronic kidney diseases and end-stage renal diseases. The company also provides RDX009, a non-systemic agent for treating type 2 diabetes that stimulate TGR5, a receptor found in the gastro-intestinal tract; and RDX013, a program that emphasizes non-systemic colonic potassium channel openers to increas...

Detailed Description

34175 Ardenwood Boulevard

Fremont, CA 94555

United States

Founded in 2007

Phone:

510-745-1700

Fax:

510-745-0493

www.ardelyx.com

Key Executives for Ardelyx, Inc.

Chairman and Chief Executive Officer
Age: 47
Co-Founder and Director
Co-Founder
Co-Founder
Age: 55
Vice President of Finance & Operations
Age: 60
Compensation as of Fiscal Year 2012.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Presents at Leerink Swann Global Healthcare Conference, Feb-14-2013 09:00 AM
Feb 7 13

Ardelyx, Inc. Presents at Leerink Swann Global Healthcare Conference, Feb-14-2013 09:00 AM. Venue: Waldorf Astoria Hotel, New York, New York, United States. Speakers: Michael G. Raab, Chairman and Chief Executive Officer.

Ardelyx, Inc. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12

Ardelyx, Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.

AstraZeneca PLC and Ardelyx, Inc. Sign Licensing Agreement for NHE3 Inhibitor Programme
Oct 9 12

AstraZeneca PLC and Ardelyx, Inc. have signed a exclusive licensing agreement for Ardelyx's NHE3 inhibitor programme for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The NHE3, the sodium-hydrogen antiporter 3, inhibitor programme includes the Phase 2-ready lead compound RDX5791. The partnership will focus on developing RDX5791 for use in ESRD and CKD in addition to irritable bowel syndrome and evaluating possible development in other diseases that are a consequence of sodium and fluid overload. AstraZeneca CVGI Innovative Medicines vice president and head Gunnar Olsson said the licensing agreement will enable the development of new medicines for people with renal complications, including those resulting from diabetes. With a novel mechanism of action, RDX5791 has the potential to have a major impact on how doctors treat these patients.

Similar Private Companies By Industry

Company Name Region
Kolltan Pharmaceuticals, Inc. United States
SetPoint Medical Corporation United States
Kaire Nutraceuticals, Inc. United States
Large Scale Bioprocessing, Inc. United States
Pervasis Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date		 Target
No transactions available in the past 12 months.
Report Data IssueReport Data Issue
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.

Close